000063186 001__ 63186
000063186 005__ 20200103141019.0
000063186 0247_ $$2doi$$a10.1371/journal.pone.0184181
000063186 0248_ $$2sideral$$a101947
000063186 037__ $$aART-2017-101947
000063186 041__ $$aeng
000063186 100__ $$aMárquez-Rodas, I.
000063186 245__ $$aFrequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM “El Álamo III” retrospective study
000063186 260__ $$c2017
000063186 5060_ $$aAccess copy available to the general public$$fUnrestricted
000063186 5203_ $$aPurpose: To determine the frequency of breast cancer (BC) patients with hereditary risk features in a wide retrospective cohort of patients in Spain. Methods: a retrospective analysis was conducted from 10, 638 BC patients diagnosed between 1998 and 2001 in the GEICAM registry “El Álamo III”, dividing them into four groups according to modified ESMO and SEOM hereditary cancer risk criteria: Sporadic breast cancer group (R0); Individual risk group (IR); Familial risk group (FR); Individual and familial risk group (IFR) with both individual and familial risk criteria. Results: 7, 641 patients were evaluable. Of them, 2, 252 patients (29.5%) had at least one hereditary risk criteria, being subclassified in: FR 1.105 (14.5%), IR 970 (12.7%), IFR 177 (2.3%). There was a higher frequency of newly diagnosed metastatic patients in the IR group (5.1% vs 3.2%, p = 0.02). In contrast, in RO were lower proportion of big tumors (> T2) (43.8% vs 47.4%, p = 0.023), nodal involvement (43.4% vs 48.1%, p = 0.004) and lower histological grades (20.9% G3 for the R0 vs 29.8%) when compared to patients with any risk criteria. Conclusions: Almost three out of ten BC patients have at least one hereditary risk cancer feature that would warrant further genetic counseling. Patients with hereditary cancer risk seems to be diagnosed with worse prognosis factors.
000063186 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000063186 590__ $$a2.766$$b2017
000063186 591__ $$aMULTIDISCIPLINARY SCIENCES$$b15 / 64 = 0.234$$c2017$$dQ1$$eT1
000063186 592__ $$a1.164$$b2017
000063186 593__ $$aAgricultural and Biological Sciences (miscellaneous)$$c2017$$dQ1
000063186 593__ $$aMedicine (miscellaneous)$$c2017$$dQ1
000063186 593__ $$aBiochemistry, Genetics and Molecular Biology (miscellaneous)$$c2017$$dQ1
000063186 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000063186 700__ $$aPollán, M.
000063186 700__ $$aEscudero, M.J.
000063186 700__ $$aRuiz, A.
000063186 700__ $$aMartín, M.
000063186 700__ $$aSantaballa, A.
000063186 700__ $$aMartínez del Prado, P.
000063186 700__ $$aBatista, N.
000063186 700__ $$0(orcid)0000-0003-0123-4274$$aAndrés, R.$$uUniversidad de Zaragoza
000063186 700__ $$0(orcid)0000-0002-9159-4988$$aAntón, A.$$uUniversidad de Zaragoza
000063186 700__ $$aLlombart, A.
000063186 700__ $$aFernandez Aramburu, A.
000063186 700__ $$aAdrover, E.
000063186 700__ $$aGonzález, S.
000063186 700__ $$aSeguí, M.A.
000063186 700__ $$aCalvo, L.
000063186 700__ $$aLizón, J.
000063186 700__ $$aRodríguez Lescure, Á.
000063186 700__ $$aRamón y Cajal, T.
000063186 700__ $$aLlort, G.
000063186 700__ $$aJara, C.
000063186 700__ $$aCarrasco, E.
000063186 700__ $$aLópez-Tarruella, S.
000063186 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000063186 773__ $$g12, 10 (2017), 0184181 [10 pp]$$pPLoS One$$tPloS one$$x1932-6203
000063186 8564_ $$s819769$$uhttps://zaguan.unizar.es/record/63186/files/texto_completo.pdf$$yVersión publicada
000063186 8564_ $$s106327$$uhttps://zaguan.unizar.es/record/63186/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000063186 909CO $$ooai:zaguan.unizar.es:63186$$particulos$$pdriver
000063186 951__ $$a2020-01-03-14:00:44
000063186 980__ $$aARTICLE